Dolutegravir, Abacavir and Lamivudine ( DrugBank: Lamivudine, Abacavir, Dolutegravir )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05193994 (ClinicalTrials.gov)	February 24, 2022	6/12/2021	Triumeq in Amyotrophic Lateral Sclerosis	Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Dolutegravir, Abacavir and Lamivudine;Drug: Placebo	Macquarie University, Australia	King's College London;Stichting TRICALS Foundation	Recruiting	18 Years	N/A	All	390	Phase 3	Australia